In the wake of FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD new drug application (NDA), many individuals and organisations associated with the company are trying to make sense of their professional futures—not least the 75% of the company’s staff who were laid off last month. But beyond the company’s own staff and vendors, a whole host of researchers who…
